Kenvue stock edges lower as Q2 2026 results miss expectations

Published on 09/01/2026 at 22:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kenvue stock is trading below 19 USD as of early September 2026 after its latest quarterly earnings slightly missed analyst expectations and revenue grew modestly, while the consumer health group continues to offer a dividend yield above 4 percent.

Fotorealistische Aufnahme einer modernen Konsumgüter-Verpackungslinie in heller Fabrikhalle — Fotorealistische moderne Konsumgüterfabrik mit Verpackungslinie symbolisiert Körperpflegeproduktion des Unternehmens Kenvue mit ISIN US49177J1025, Illustration mit AI erstellt.

Kenvue stock (ISIN US49177J1025) is quoted around 18.90 USD on the New York Stock Exchange as of September 1, 2026, leaving the consumer health group trading close to where it was in recent weeks and below many analyst target prices, while offering a dividend yield of about 4.4 percent according to data compiled by MarketBeat.

Q2 2026 earnings miss consensus by a narrow margin

According to a recent overview from MarketBeat, Kenvue reported adjusted earnings per share of 0.31 USD for its latest quarter, released on August 6, 2026, slightly below the analyst consensus of 0.32 USD for the same period.

In the same quarter, Kenvue generated revenue of 3.96 billion USD, compared with analyst expectations of 3.97 billion USD, meaning sales undershot the consensus by 0.01 billion USD while still growing 3.0 percent year over year from 3.85 billion USD in the comparable period a year earlier as summarized in the same source.

Solid profitability and dividend support the valuation

The MarketBeat data also show that Kenvue achieved a net margin of 10.76 percent and a return on equity of 21.22 percent in this recent quarter, underlining that the business remains clearly profitable despite the small earnings and revenue miss.

For income oriented investors, a key figure is the quarterly dividend of 0.21 USD per share, which was most recently paid on August 26, 2026 to shareholders of record as of August 12, 2026, corresponding to an annualized dividend of 0.84 USD and a yield of roughly 4.4 percent on the current share price based on the same MarketBeat compilation.

Analysts tracked in that overview expect Kenvue to earn 1.14 USD per share in the current fiscal year 2026, so the stock is trading at a mid teens earnings multiple on these projections, which sets the valuation context for investors comparing the company with other global consumer and healthcare names including large European peers.

Go deeper

More background on Kenvue stock

Key figures, news and regulatory information on Kenvue can be found in the topic overview on ad-hoc-news.de and on the company investor pages.

All Kenvue reports on ad-hoc-news.de Investor Relations

Consumer health portfolio with brands like Tylenol

Kenvue positions itself as a global consumer health company with a broad portfolio of over the counter medicines, skin care and self care products, including well known brands such as Tylenol pain relief and popular oral care labels as described in company materials and financial portal summaries.

Kenvue stock remains near 19 USD

MarketBeat quotes Kenvue shares at 18.90 USD as of the latest trading data on September 1, 2026, which places the stock just below the 19.18 USD level of its 50 day moving average and marginally above its 18.25 USD 200 day moving average, indicating a fairly narrow trading range over recent months.